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Abstract: Major depressive disorder (MDD) is among the most incapacitating conditions in 
the world. The emergence of the selective serotonin reuptake inhibitor (SSRI) and serotonin 
norepinephrine reuptake inhibitors (SNRI) antidepressants has improved the treatment of MDD. 
Desvenlafaxine succinate (DVS) is the succinate salt of the isolated major active metabolite of 
venlafaxine, O-desmethylvenlafaxine: it is the third SNRI to become available in the United 
States, and was approved in 2008 by the US Food and Drug Administration (FDA) for the 
treatment of MDD. Early investigations showed therapeutic efﬁ  cacy for doses between 50 and 
400 mg/day; however in doses above 100 mg/day there were incremental increases in side effects. 
Nausea was the most frequent adverse effect. Hence the recommended dosing for DVS is in 
the 50 to 100 mg range. Desvenlafaxine is excreted in urine, it is minimally metabolized via 
the CYP450 pathway, and is a weak inhibitor of CYP2D6. A reduced risk for pharmacokinetic 
drug interactions is a potential advantage over other SNRI. Further head-to-head trials involving 
comparisons of DVS in the 50 to 100 mg dose range with currently available SSRI and SNRI 
antidepressants are required. Evidence for relapse prevention is available in the 200 to 400 mg 
dose range, but this needs to be demonstrated in the 50 to 100 mg dose range, as well as health 
economic measures and quality of life evaluations.
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Introduction
Major depressive disorder (MDD) is the single most frequent psychiatric disorder in 
the USA, with an estimated lifetime prevalence of 16.6% and is among the most inca-
pacitating conditions in the world.1 According to the Global Burden of Disease Study, 
using disability adjusted life-years (DALYs) as a measure of lost years of healthy life, 
depression was ranked fourth in 20002 and is estimated to rank ﬁ  rst in 2030.3 Depres-
sion was the foremost cause of years lived with disability for both men and women 
in 2001.4 In Canada, the lifetime prevalence of MDD was 11.2%.5
Depression is often comorbid with chronic medical diseases and can worsen 
associated health outcomes. The prevalence of depression in a large population based 
health outcomes study was estimated for those respondents who suffered from chronic 
physical diseases (angina, arthritis, asthma and diabetes).6 Comorbid depression was 
identiﬁ  ed in 9% to 23% of individuals with one or more chronic physical disease, 
signiﬁ  cantly higher than the likelihood of having depression in the absence of a chronic 
physical disease (p  0.0001). These ﬁ  ndings emphasize the importance of providing 
safe and effective treatment to people with a diagnosis of MDD, including those with 
comorbid medical disorders.
Despite signiﬁ  cant advances in the treatment of MDD, between 30% and 50% of 
depressed patients have an inadequate response to the ﬁ  rst antidepressant therapy. MDD 
often recurs, and an incomplete recovery from an index episode has been shown to 
increase the risk of chronicity and recurrence.7 The emergence of the selective serotonin Neuropsychiatric Disease and Treatment 2009:5 128
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reuptake inhibitors (SSRI) and serotonin norepinephrine 
reuptake inhibitors (SNRI) antidepressants has improved the 
treatment of MDD. Nevertheless, data from the Sequenced 
Treatment Alternatives to Relieve Depression (STAR*D) 
trial indicate that approximately 70% of the patients with 
MDD do not achieve remission following adequate treat-
ment with a single SSRI,8 and the incremental likelihood 
of achieving remission progressively diminishes over three 
further interventions.9
The serotonin and norepinephrine 
reuptake inhibitors
The ﬁ  rst dual reuptake SNRI antidepressant was the immediate-
release form of venlafaxine, launched in the United States in 
1994. The extended-release (ER) formulation, venlafaxine 
XR, followed in 1997, resulting in better tolerability and com-
parable or superior efﬁ  cacy. As a follow up to the initial report 
of clinically meaningful differences in rates of remission 
between venlafaxine and SSRIs,10 Nemeroff and colleagues 
expanded the meta-analysis to include all identiﬁ  ed compara-
tive trials involving venlafaxine and an SSRI (Comprehensive 
Analysis of Remission – COMPARE).11 They reported 
that “venlafaxine therapy is statistically superior to SSRIs 
as a class, but only to ﬂ  uoxetine individually,” and noted 
that attrition rates due to adverse events were higher with 
venlafaxine than with SSRIs. Underscoring the complexi-
ties of meta analytic approaches, Weinmann et al12 included 
17 venlafaxine versus SSRI studies, and did not ﬁ  nd evidence 
that venlafaxine has superior efﬁ  cacy or a better side effect 
proﬁ  le than SSRI. There is no evidence that venlafaxine is 
superior to escitalopram.13,14
Ten years after the launch of venlafaxine, duloxetine was 
introduced in the USA (2004), and has become widely avail-
able throughout the world. In a meta-analysis of 6 randomized 
studies, duloxetine had superior efﬁ  cacy than both ﬂ  uoxetine 
20 mg/day and paroxetine 20 mg/day in the treatment of patients 
with moderate to severe depression.15 In comparison to escitalo-
pram, duloxetine has not displayed any clinical advantage.16,17 
Although milnacipram, an SNRI with preferential inhibitory 
effects on the norepinephrine transporter, is available as an 
antidepressant across many European countries and in Japan, 
it has not been licensed in North America, and is currently 
being evaluated for the treatment of ﬁ  bromyalgia.
Desvenlafaxine succinate
Desvenlafaxine succinate (DVS) is the third SNRI to become 
available in the United States. It is indicated for the treatment 
of MDD although it has also been investigated as a treatment 
for vasomotor symptoms associated with menopause18,19,20 
and for the treatment of ﬁ  bromyalgia.21
Pharmacodynamics and pharmacokinetics
DVS is the succinate salt of the isolated major active metabo-
lite of venlafaxine, “O-desmethylvenlafaxine” (Figure 1). 
Venlafaxine is metabolized in the liver through the cytochrome 
P450 system into three metabolites: O-desmethylvenlafaxine, 
N-desmethylvenlafaxine, and N, O-desmethylvenlafaxine.
DVS displays competitive binding interactions at both 
the human serotonin (5-HT) transporter (hSERT; Ki = 40 ± 
1.6 nM) and the human norepinephrine (NE) transporter 
(hNET; Ki = 558 ± 121.6 nM), with only weak afﬁ  nity for 
the human dopamine (DA) transporter (hDAT; Ki = 25 μM). 
In vitro functional assays indicate that DVS is approximately 
10-fold more potent as an inhibitor of 5-HT uptake than NE 
uptake.22–24 Afﬁ  nity for muscarinic, cholinergic, histamine 
H1−, and alpha1 adrenergic receptors is very low.22,23
DVS increases extracellular levels of both NE and 5-HT 
without increasing DA levels in the hypothalamus of ovari-
ectomized rats.18 In male rats, DVS is brain-penetrable and 
increases neurotransmitters in the hypothalamus, a region of 
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the brain involved in pain sensation as well as temperature 
and mood regulation.22
DVS is designated RS-4-[2-dimethylamino-1(hydrox
ycyclohexyl)ethyl]phenol, with an empirical formula of 
C16H25NO2 (free base) and C16H25NO2•C4H6O4•H2O (succi-
natemonohydrate) and a molecular weight of 399.48.25
It is formulated as a sustained release tablet (50 mg or 
100 mg) for once-a-day oral administration. Single-dose stud-
ies indicate linear and dose-proportional pharmacokinetics in 
a dose range between 100 mg/day to 600 mg/day. The mean 
terminal half-life (t1/2) is approximately 11 hours,26 with maxi-
mum plasma concentration (Tmax) within 7.5 hours of oral 
administration. With once-daily dosing, steady-state plasma 
concentrations are achieved within approximately 4 to 5 days, 
and multiple-dose accumulation of DVS is linear and predict-
able. The absolute bioavailability of the oral formulation is 
80%, and absorption is minimally affected by food.27,28
DVS sustained release was considered safe in healthy 
volunteers up to a single dose of 750 mg27 and was well tol-
erated in multiple doses up to 450 mg.28 The plasma protein 
binding of DVS is low (30%) and is independent of drug 
concentration. This is likely to result in high brain concen-
tration of the drug. It is also a weak inhibitor of CYP2D6. 
To examine the clinical implications, the effects of DVS 
100 mg and duloxetine 30 mg bid on plasma levels of desip-
ramine were compared in healthy subjects in a randomized, 
open label, crossover study.29 In comparison to desipramine 
alone, co-administration of duloxetine resulted in increases in 
AUC and Cmax of desipramine (122% and 63% respectively). 
These were signiﬁ  cantly greater than the increases observed 
with DVS co-administration (22% and 19%, respectively), 
suggesting that DVS is not a clinically signiﬁ  cant inhibitor 
of CYP2D6 activity.
DVS is primarily metabolized by conjugation and, to a 
minor extent, through CYP3A4 mediated oxidative metabo-
lism. Approximately 45% is excreted unchanged in urine at 
72 hours after oral ingestion, while 20% of the administered 
dose is excreted as the glucuronide metabolite and 5% 
as the oxidative metabolite (N, O-didesmethylvenlafaxine) 
in urine.25
Effect of hepatic and renal impairment
DVS 100 mg has been examined in a small sample of hepati-
cally impaired subjects and matched healthy adults. There 
was a lower clearance and longer t1/2 only in subjects with 
moderate to severe hepatic impairment.30 Thus, there does not 
appear to be any need to reduce the starting dose for patients 
with mild hepatic impairment.
Since DVS is almost entirely excreted in urine, patients 
with renal impairment present a greater clinical concern. 
The disposition of DVS after administration of 100 mg was 
studied in subjects with mild (n = 9), moderate (n = 8), severe 
(n = 7) and end stage renal disease (n = 9), and in healthy, 
age-matched control subjects (n = 8). Elimination was sig-
niﬁ  cantly correlated with creatinine clearance. Increases in 
AUC compared to the control group were proportional to the 
degree of renal impairment: mild 42%; moderate 46%; severe 
108% and end stage 116%. The mean terminal half-life (t1/2) 
was prolonged. Dosage adjustment to alternate day dosing 
is recommended in patients with signiﬁ  cant impairment of 
renal function.25
Efﬁ  cacy in clinical trials
As of October 2008, 6 published DVS efﬁ  cacy trials in 
MDD were identiﬁ  ed.31–36 Several published abstracts were 
also reviewed: including a ﬂ  exible dose trial of DVS 200 to 
400 mg,37 a trial comparing DVS 50 and 100 mg to placebo 
with a duloxetine reference arm,8 as well as two unpublished 
pooled analyses, the ﬁ  rst involving 7 short-term trials with 
DVS doses between 100 and 400 mg39 and the second from 
2 trials with DVS at 50 and 100 mg.40 Other studies of DVS 
as a treatment for vasomotor symptoms of menopause and 
pain were not reviewed. No published trials for generalized 
anxiety disorder or other anxiety disorders were located.
Clinical trial design
Five of the published studies for DVS in the treatment of 
MDD were placebo controlled RCTs, and one was a pooled 
analysis from 2 otherwise unpublished clinical trials.
The initial dose ﬁ  nding trials examined doses of 100, 
200 or 400 mg/day,31–33 while subsequent trials evaluated 
daily doses of 50 and 100 mg.34,35 Of 5 individual published 
clinical trials, 4 had a similar ﬁ  xed-dose design while 1 was 
a ﬂ  exible dose study.
The inclusion criteria were generally similar and involved 
outpatients with a primary diagnosis of MDD, single or 
recurrent episodes, without psychotic features, between 18 
and 75 years of age, although two trials34,35 did not deﬁ  ne 
an upper age limit. Depressive symptoms had to have been 
present for at least 30 days before the screening visit, and a 
minimum score of 20 on the 17-item Hamilton Rating Scale 
for Depression (HAM-D17) was required.
Usual exclusion criteria were applied, including a diag-
nosis of bipolar Ddisorder. Participants were also excluded 
if they had previously received treatment with DVS or ven-
lafaxine within 90 days of the baseline. Three of the trials, in Neuropsychiatric Disease and Treatment 2009:5 130
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which the doses of DVS ranged from 100 to 400 mg/day,31–33 
excluded depressed patients with high levels of anxiety 
(deﬁ  ned as a Covi Anxiety Scale total score greater than 3 on 
any single item, a total score greater than 9, or a score greater 
than the Raskin Depression Scale total score). The length of 
the treatment for all the studies was 8 weeks, followed by 
one or 2 weeks of tapering, and a follow up visit 7 days after 
the last dose. An option to enroll in a long-term open label 
extension study was offered to the patients who participated 
in three of these studies.31–33
DVS trials in doses of 100 mg/day 
and higher
In all trials, the 17-item version of the Hamilton Rating 
Scale for Depression (HAM-D17)41 was the primary efﬁ  cacy 
measure and the Clinical Global Impressions-Improvement 
scale (CGI-I) was a secondary efﬁ  cacy measure. Other 
secondary measures included the Montgomery-Asberg 
Depression Rating Scale (MADRS), Clinical Global Impres-
sions-Severity scale (CGI-S), and Visual Analog Scale-Pain 
Intensity (VAS-PI). In four of the trials,32–35 the Covi Anxiety 
Scale, Sheehan Disability Scale (SDS) and World Health 
Organization 5-item Well Being Index (WHO-5) were also 
secondary outcome measures. One study35 also included a 
subscale of core depressive symptoms, the HAM-D6.42 The 
primary end point for all efﬁ  cacy measures was the “ﬁ  nal on 
therapy” (FOT) evaluation of the intent-to-treat (ITT) popu-
lation, using the last-observation-carried-forward (LOCF) 
method to account for missing data.
In the ﬁ  rst trial by DeMartinis et al32 480 subjects were 
randomized to receive DVS 100, 200 or 400 mg/day, or 
placebo. The doses were up titrated over 8 days. During 
the taper phase, doses were reduced to the next lower dose 
at weekly intervals. This study reported a signiﬁ  cant drug-
placebo difference in adjusted mean change from baseline 
in the HAM D17 for DVS 100 mg/day (−10.60; p = 0.0038) 
and 400 mg/day (–10.74; p = 0.0023) compared to placebo 
(−7.65), but not for DVS 200 mg/day (−9.63; p = 0.0764). 
Among the secondary end points, there was a signiﬁ  cant 
difference in favor of DVS at both doses on CGI-I. Adjusted 
odds ratio for response rates compared to placebo, were 2.16 
(95% CI = 1.25–3.73) for 100 mg DVS (p = 0.0060), 1.60 
(95% CI = 0.93–2.76) for 200 mg DVS (p = 0.089), and 
1.92 (95% CI = 1.11–3.32) for 400 mg DVS (p = 0.020.). 
These differences correspond to response rates of 52% for 
DVS 100 mg and 48% for DVS 400 mg.
For remission, the adjusted odds ratios in relation to 
placebo were: 1.87 (95% CI = 0.99–3.52) for DVS 100 mg 
(p = 0.053), 1.73 (95% CI = 0.92–3.26) for 200 mg DVS 
(p = 0.088) and 2.20 (95% CI = 1.17–4.14) for 400 mg 
DVS (p = 0.014). This corresponds in the DVS 400 mg group 
to a 33% remission rate. Participants taking DVS 100 mg 
also showed signiﬁ  cantly greater improvement in the overall 
pain measure compared to the placebo group.
In the second trial by by Septien-Velez and colleagues,31 
375 patients were randomized to receive DVS 200 or 
400 mg/day, or placebo. Patients assigned to the 400 mg/day 
dose, had a 1-week escalation period. There was a signiﬁ  cantly 
greater reduction in HAM-D17 from baseline for both DVS 
200 mg/day (−12.6 ± 0.75; p = 0.002) and DVS 400 mg/day 
(−12.1 ± 0.74; p = 0.008) compared with placebo (−9.3 ± 
0.74) on the ﬁ  nal evaluation. There were also signiﬁ  cant 
differences in mean CGI-I scores versus placebo for both 
doses of DVS. Both DVS 200 mg/day (p  0.001) and 
400 mg/day (p = 0.005) yielded signiﬁ  cantly higher rates of 
response (60% and 57% respectively compared to 39% on 
placebo) although remission was signiﬁ  cant only for DVS 
200 mg/day (38% vs 22%, p = 0.017).
In a third and negative trial,33 247 patients were random-
ized to receive DVS 200 mg/day (that could be lowered 
to 100 mg/day if indicated) or placebo. During the discon-
tinuation phase, patients on DVS 200 mg received 1 week at 
100 mg. The adjusted mean change from baseline on HAM-D17 
was 14.1 for DVS (100–200 mg/day) versus 15.1 for placebo 
(not signiﬁ  cant). Similarly the CGI-I scores (2.5 for DVS 
group and 2.7 for placebo) were not statistically signiﬁ  cantly 
different, although other secondary measures including 
MADRS (p = 0.047) and VAS-PI overall pain (p = 0.008) 
were statistically different from placebo. Neither were there 
statistically signiﬁ  cant differences between DVS and placebo 
rates of response or remission.
A pooled analysis presented results from 2 otherwise 
unpublished double blind, venlafaxine ER-referenced ﬂ  exible 
dose RCTs.36 Each was a negative trial for DVS, but assay 
sensitivity was conﬁ  rmed in the venlafaxine group. Data on 
DVS from both studies were pooled post hoc, and yielded 
positive results. The treatment groups were: DVS (target dose 
200 mg/day, with option to increase to 400 mg/day after day 28), 
venlafaxine ER 75 mg/day to 150 mg/day (Europe) or venla-
faxine ER 150 mg/day to 225 mg/day (USA) or placebo. The 
following minimum scores were required at the screening and 
baseline visits: HAM-D17  22, score  2 on item 1, CGI-S  4 
(moderately ill) and a greater score on the Raskin Depression 
Scale than the Covi Anxiety Scale. Patients with comorbid 
Generalized Anxiety Disorder, Panic Disorder, or Social 
Anxiety Disorder were allowed to participate if MDD was the Neuropsychiatric Disease and Treatment 2009:5 131
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primary diagnosis. The length of the treatment was 8 weeks, plus 
a taper period based on the ﬁ  nal dose for the three arms.
All efﬁ  cacy analyses included the ITT population (713 
subjects). Data from the venlafaxine ER groups were not 
pooled due to the difference in doses in the two trials. The 
longitudinal changes from baseline on pooled data for the 
primary efﬁ  cacy measure and the secondary measures were 
analyzed using a mixed-effect model for repeated measures 
(MMRM). A logistic regression model was used for binary 
outcome variables: response and remission measured by the 
HAM-D17 and CGI-I.
The change on HAM-D17 total score from baseline was 
greater for DVS than for placebo, with a magnitude of 
effect = −2.34; (p  0.001). Statistically signiﬁ  cant differ-
ences in CGI-I scores for DVS versus placebo were observed 
(2.0 versus 2.3; p  0.001); both venlafaxine ER groups were 
signiﬁ  cantly different from placebo at week 8 for HAM-D17 
total score (p = 0.001 and p  0.001) and CGI-I scores 
(p = 0.003 and p  0.001).
The differences in HAM-D17 response and remission rates 
for DVS compared to placebo were not statistically signiﬁ  cant. 
For both venlafaxine ER groups, response rates versus placebo 
were signiﬁ  cant, although remission rate was signiﬁ  cant only 
for venlafaxine ER 150 to 225 mg/day (p = 0.003). CGI-I 
response rates were not statistically signiﬁ  cant for DVS versus 
placebo, but were statistically signiﬁ  cant for both venlafaxine 
ER groups (75–150 mg and 150–225 mg).
The treatment effect of DVS (dose range 200–400 mg) 
observed using MMRN analysis was 2.3 points on the 
HAM-D17, and it was in line with that observed for venla-
faxine ER 75 to 150 mg/day (2.4) and venlafaxine ER 150 to 
225 mg/day (2.7) in the individual studies. Desvenlafaxine 
was considered efﬁ  cacious to treat MDD in the pooled 
analysis of the data using MMRM models.
DVS trials in doses of 50 mg and 100 mg
In both published trials,34,35 eligible patients were randomly 
assigned to receive DVS 50 or 100 mg/day or placebo, and 
results were inconsistent. In the ﬁ  rst low-dose trial,34 the 
adjusted mean change from baseline in HAM-D17 total score 
was signiﬁ  cantly greater for both DVS 50 mg/day (−13.2; 
p = 0.002) and DVS 100 mg/day (−13.7; p  0.001) versus 
placebo (–10.7). Signiﬁ  cant differences were observed start-
ing at week 4 for DVS 100 mg/day and at week 6 for DVS 
50 mg/day. CGI-I scores in the DVS 50 mg/day and DVS 
100 mg/day groups were signiﬁ  cantly lower than placebo at end 
point (p = 0.003 and p  0.001, respectively). Rates of response 
were signiﬁ  cantly greater for DVS 50 mg/day (65%; p = 0.005) 
and 100 mg/day (63%; p = 0.018) versus placebo (50%), 
although remission rates were signiﬁ  cantly different only for 
DVS 100 mg/day (45% DVS versus 29% placebo, p = 0.003), 
but not for DVS 50 mg (37% versus 29%; p = 0.100). Based 
on differences in response and remission rates, these results 
would translate into number needed to treat (NNT) values of 
6 to 7 patients to achieve response at 50 and 100 mg doses, 
and NNT = 6 for remission on DVS 100 mg.
In the second study35 the HAM-D17 adjusted mean change 
from baseline was signiﬁ  cantly greater for DVS 50 mg/day 
compared to placebo (1.9, p = 0.018), but not for DVS 
100 mg/day (1.5, p = 0.065), although signiﬁ  cant differences 
for DVS 100 mg/day at 8 weeks versus placebo were identi-
ﬁ  ed using two other methods of statistical analysis.
The differences on the HAM-D6 sub scale were signiﬁ  cant 
for DVS 50 mg (difference in adjusted means: 1.3; p = 0.010) 
and DVS 100 mg/day (difference in adjusted means: 1.0; 
p = 0.038). Signiﬁ  cant differences were observed for DVS 
50 mg/day (2.7, p = 0.022) in the adjusted mean score for 
MADRS, WHO-5 and SDS total score (WHO-5: p = 0.020, 
SDS: p = 0.012) but not for DVS 100 mg/day. There were 
no statistically signiﬁ  cant differences from placebo in either 
DVS 50 mg/day or 100 mg/day groups for CGI-I, CGI-S or 
Covi Anxiety Scale scores.
Using logistic regression analysis, response rates for 
HAM-D17, MADRS, and CGI-I did not differ statistically 
among groups, although remission rates were greater in the 
DVS 50 mg/day group compared to placebo (logistic regression 
analysis, 34% versus 24%; p = 0.027) (Figures 2 and 3).
Additional preliminary data have been presented at 
scientiﬁ  c meetings. Liebowitz, Montgomery, Boyer et al 
(2007)40 reported that once-daily DVS 50 and 100 mg/day 
demonstrated signiﬁ  cantly greater improvements at week 8 
compared with placebo on measures of efﬁ  cacy in two-
placebo controlled trials. A pooled analysis from 7 short-term 
placebo-controlled trials reported that DVS was an effective 
treatment for MDD, and no additional beneﬁ  t was observed 
with DVS doses above 100 mg/day.39 Data from an unpub-
lished duloxetine referenced short-term study on ﬁ  xed doses 
of DVS 50 mg/day and 100 mg/day to treat MDD, failed to 
conﬁ  rm superiority for DVS 50 mg/day compared to placebo, 
but there were statistically signiﬁ  cant differences for DVS 
100 mg and duloxetine 60 mg compared to placebo.38
Special populations
There are ongoing clinical trials in several sub popula-
tions of MDD patients. Two studies involve children and 
adolescents.21 A long-term safety and tolerability open trial Neuropsychiatric Disease and Treatment 2009:5 132
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Figure 2 Desvenlafaxine succinate response rates by dose across studies.
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Figure 3 Desvenlafaxine succinate remission rates by dose across studies.
of DVS (ﬂ  exible doses: 100–200 mg/day) in elderly MDD 
patients has been completed, and results show that the adverse 
events are similar in type and frequency to those observed 
in adults.21 DVS has also been compared to escitalopram in 
postmenopausal women.21 There are no data to support the 
use of DVS during pregnancy and lactation.
Relapse prevention and maintenance trials
In a 6-month relapse prevention trial, the DVS group (dose 
range 200–400 mg/day) had signiﬁ  cantly fewer relapses 
(24%) compared to the placebo group (42%).43 There are no 
reports of relapse prevention in the 50 to 100 mg/day dose 
range of DVS.
Results from an open label, 12-month, ﬂ  exible dose trial 
of DVS (mean  300 mg/day) showed a steady decrease in 
HAM-D17 total score from baseline of approximately nine 
points, and statistically signiﬁ  cant improvements from base-
line in disability measures assessed by the SDS.44
Safety and tolerability
The incidence of treatment-emergent adverse events (TEAEs) 
in the published trials, deﬁ  ned as adverse events reported by Neuropsychiatric Disease and Treatment 2009:5 133
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at least 5% of participants in the treatment group occurring 
at least twice as frequently as on placebo, revealed a linear 
relationship between TEAEs and DVS dose: DVS 50 mg/day–
78% to 84%; DVS 100 mg/day–76% to 90%; DVS 200 to 
400 mg/day –85% to 93%. The placebo reported frequencies 
of TEAEs ranged from 62% to 84%. In most cases the TEAEs 
were mild to moderate.
Nausea was the most frequently reported adverse event: 
17% to 27% of patients receiving 50 mg/day,34,35 and 16%, 
30% and 35% respectively in each of the 100 mg studies32,34,35 
reported nausea, although in all cases, rates declined mark-
edly after 1 to 2 weeks. For patients taking DVS 200 mg/day 
or 400 mg/day, nausea was reported with a frequency rang-
ing from 30% to 46%.31,32,33 Nausea was higher in the DVS 
(200 and 400 mg/day) groups (38%) compared to both venlafax-
ine groups (75–150 mg/day: 21%; 150–225 mg/day: 29%).36
The most frequently reported TEAEs other than nausea 
were: insomnia, somnolence, dry mouth, dizziness, sweating, 
nervousness, anorexia, constipation, asthenia, and sexual 
dysfunction (Table 1).
The overall discontinuation rate was comparable across 
studies and was approximately 23%: DVS groups ranged 
from 22% to 30%, and placebo from 16% to 21%. Discon-
tinuation rates were lower in the study reported by Boyer 
et al34 with an overall rate of 10.3%: 10.2% for the DVS 
50 mg/day group; 12.7% for the DVS 100 mg/day group and 
8.1% for placebo discontinuation. The number of completers 
in the DVS group (72%) was lower than in either venlafaxine 
ER group (75–150 mg/day: 85%; 150–225 mg/day: 77%) or 
placebo (86%) in the pooled analysis.36
Nausea was the most common reason cited for discontinu-
ation among DVS patients in all studies, except for one study 
with DVS 200 mg (ﬂ  exible dose)33 where insomnia (3%) was 
the most frequent reason for discontinuation.
Discontinuation emergent symptoms
The impact of rapid discontinuation of DVS was also evaluated 
in several trials.32,34,35 Using the Discontinuation Emergent 
Signs and Symptoms (DESS) checklist45 to assess symptoms 
that ﬁ  rst occurred or worsened during the taper period. Only 
a minority of patients (87) entered the abrupt taper analysis in 
the DeMartinis et al32 study because most patients entered the 
open label extension trial. The most frequent discontinuation 
emergent events following DVS were nausea (6%), abnormal 
dreams (5%), and infection (5%) compared to headache 
(9%) and anxiety (9%) in the placebo discontinuation group. 
Following discontinuation from low-dose DVS 50 and 100 
mg/day, the most common (5%) taper emergent events 
were: dizziness, nausea, headache, irritability, abnormal 
dreams, insomnia, and diarrhea, with a reported increase 
(+2.1, p = 0.001) in mean DESS scores for DVS 50 mg/day 
arm compared to placebo arm (0.2) at the end of week one 
of the taper period.35 In the other low-dose trial, DESS 
scores were analyzed at 1, 2 and 3 weeks after treatment. 
Table 1 Adverse events across studies (%)
 Placebo31,32,33,34,35 50 mg34,35 100 mg32,34,35 200 mg31,32,33 400 mg31,32
Nausea 8–11 17–27 16–35 30–46 41–50
Dizziness 2–12 10–17 7–17 15–16 14–19
Dry mouth 4–12 10 16–17 19–26 23–25
Constipation 3–6 8–9 5–12 9–17 14
Insomnia 8–11 8–9 9–22 17–18 30
Asthenia 3–7 6–7 7 11 10–16
Anorexia 2–3 5 4–12 12–13 10–14
Somnolence 2–8 5 13–20 10–22 6–26
Sweating 3–7 5–6 10 16–28 21–29
Sexual dysfunction 0–5 – 1.4–3 2–8 2–15
Anxiety 1–4 3 5 5 6
Abnormal Vision (including 
blurred vision)
0–1 5 3 6 2
Tremor 0–1 – 4 8–9 8–10
Tachycardia 2 – 3 3 5
Taste perversion 2 – 1 1 5
Vasodilatation 0 – 2 5 4
Yawn 0 – 3–7 5–7 2Neuropsychiatric Disease and Treatment 2009:5 134
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Results were signiﬁ  cantly higher for DVS 50 mg (p = 0.001) 
than placebo only after 1 week, and higher for DVS 100 mg 
(p = 0.017) only during week two, when patients switched 
from receiving 50 mg of DVS to no active treatment.34
One death was reported throughout the clinical trials 
program during the treatment period: a patient who was 
prescribed DVS100 mg/day committed suicide on day ﬁ  ve of 
the study, although it is not known if the patient took any of 
the medication that was dispensed at the baseline visit.32 Two 
suicide attempts were reported, one in a patient taking DVS 
100 mg/day,35 and another in a patient taking 400 mg/day.32 
One unintended pregnancy was also reported, without follow 
up information.33
Laboratory tests, vital signs, 
weight and ECG
Laboratory test results showed statistically significant 
differences from baseline to the FOT evaluation in all the 
published trials, as well as signiﬁ  cant differences versus 
placebo. These results included decreased bilirubin and 
increased gamma glutamyl transferase (GGT), alkaline 
phosphatase (ALP), aspartate aminotransferase (AST), 
and alanine aminotransferase (ALT). There were also 
increases in total cholesterol, high-density lipoprotein 
(HDL) and low-density lipoprotein (LDL) cholesterol and 
triglycerides.
In the high dose DVS trials (100–400 mg/day), 4 DVS 
patients had clinically signiﬁ  cant laboratory ﬁ  ndings in one 
study: 1 patient from the DVS 100 mg group had a clinically 
signiﬁ  cant ALT elevation (3 times upper limit of normal), 
1 in the DVS 200 mg group had increased fasting glucose 
(11.10 mmol/L), 1 in the DVS 400 mg group had increased 
total cholesterol (increase 1.29 mmol/L) and LDL choles-
terol (increase 1.29 mmol/L) and 1 patient from the same 
group had increased ALT, AST and ALP (3 times upper 
limit of normal) and GGT.32 In another study with DVS 
100 to 200 mg/day, liver enzymes were signiﬁ  cantly elevated 
compared to placebo at FOT evaluation. Three patients in the 
DVS treatment group in Septien-Velez et al (2007)31 study 
had clinically signiﬁ  cant increases in laboratory measures: 
1 patient, receiving DVS 200 mg/day, had increased AST and 
ALT; 1 patient in the same group had increased cholesterol; 
and 1 patient receiving 400 mg/day had increased cholesterol, 
triglycerides and AST.
In a third study, clinically important changes in labora-
tory tests were reported for 3 patients taking DVS 50 mg:35 
1 subject had increased fasting glucose, 1 had increased total 
cholesterol, and 1 had elevated ALT/SGPT.
Mean decreases in weight for DVS treatment groups were 
statistically signiﬁ  cant compared with baseline and placebo in 
both high and low dose trials.31–36 In the DVS 400 mg group, 
there was a statistically signiﬁ  cant decrease in weight com-
pared to the DVS 100 mg and 200 mg groups. Data pooled 
from 7 clinical trials, showed that treatment with DVS was 
associated with small mean decreases in weight in the short 
term (1 kg), which persisted up to 6 months with a small mean 
increase (1 kg) and was comparable to placebo.46
DVS groups had a small but signiﬁ  cant increase in mean 
systolic and diastolic blood pressure and a small but signiﬁ  cant 
increase from baseline in mean pulse rate. In one low dose 
trial,34 14 patients in the DVS group had clinically important 
changes in blood pressure: three patients in the DVS 50 mg/day 
arm, and 3 from the DVS 100 mg/day arm had sustained 
hypertension. To date, no data on exposure to DVS by patients 
with pre-existing hypertension have been reported.
Although a statistically signiﬁ  cant increase in QT and QTc 
interval for DVS treatment groups has been reported (exception 
Liebowitz33) that seems to be dose related, no patients had ECG 
abnormalites considered clinically relevant.
Summary and Conclusions
At this stage in the life of DVS, it is difﬁ  cult to evaluate its 
role over the next decade in the treatment of MDD. As with 
other SNRIs, the drug should be prescribed once a day. In the 
United States where the drug is available, the recommended 
dose is 50 mg daily and dose escalation above 100 mg is 
not recommended. The cost is approximately $130 monthly 
for 30 tablets (50 or 100 mg), which compares to US$100 
monthly for duloxetine 60 mg × 30 days and US$145 monthly 
for venlafaxine XR 150 mg × 30 days. Initially, the clinical 
trial program focused on doses between 100 to 400 mg daily 
and these trials have been previously reviewed.47–50 Subse-
quently, attention has shifted to trials in the 50 to 100 mg 
dose range. In the two published short-term clinical trials 
comparing daily doses of DVS 50 and 100 mg for the treat-
ment of MDD, results are inconsistent. Response rates for 
DVS 50 mg/day (54%–65%) and for 100 mg/day (51%–63%) 
were statistically superior to placebo in one trial,34 while 
50 mg, but not 100 mg was superior to placebo in the second 
trial.35 In an as yet unpublished study where venlafaxine XR 
and duloxetine were included as active comparators, there 
were no demonstrable advantages for DVS.
The advantage for DVS in the 50 to 100 mg dose range lies 
mostly in the side effect proﬁ  le. As shown in Table 1, there is 
a general trend towards increased side effect prevalence with 
increasing dose. Nausea is the most frequent adverse event Neuropsychiatric Disease and Treatment 2009:5 135
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across all doses but improves after 1 to 2 weeks of treatment. 
Cardiovascular safety was established in all reviewed trials, 
with only minimal increases in heart rate and blood pressure. 
Laboratory tests showed decrease in bilirubin levels, and 
increase in GGT, ALP, AST, ALT, total cholesterol, HDL, 
LDL, and triglycerides, demonstrating potential effects on the 
metabolic system. There is no evidence, however, that these 
effects differ from other SNRIs. There are no adverse effects 
on weight. In fact, treatment with DVS was associated with 
small mean decreases in weight in short-term trials. So far, it is 
unclear if discontinuation emergent effects for DVS are lower 
than for venlafaxine. In addition, the only relapse prevention 
trial evaluated DVS in the 200 to 400 mg dose range.
Before the practicing clinician can evaluate when to pre-
scribe DVS in the 50 to 100 mg dose range, there is clearly 
a need for more published “head to head” comparisons with 
other SNRIs (duloxetine and venlafaxine) and with SSRIs, 
particularly escitalopram.
Potential advantages for DVS over other SSRIs/SNRIs 
drugs include the narrow dose range, where the initial dose 
(50 mg) may prove to be the optimal therapeutic dose, in 
contrast to venlafaxine where extensive dose adjustments 
are frequently required. DVS has a direct pharmacodynamic 
effect, and as such has potential beneﬁ  ts over both venlafax-
ine and duloxetine. Since the drug is mainly excreted in urine 
and has minimal effects on the CYP450 pathway, its use in 
medically ill patients may be preferred over other SNRIs, 
although reductions in dosing are necessary in patients with 
signiﬁ  cant renal impairment. The drug may also preferred in 
population where depression coexists with pain or vasomo-
tor symptoms of menopause. Results from ongoing clinical 
trials should clarify the role of DVS in the treatment of MDD, 
speciﬁ  cally in patients from special populations.
Information sources
PubMed, PsycINFO, Ovid MEDLINE, CLCMR, CINAHL, 
CDSR, ACP Journal Club, DARE, CCTR, CLHTA, CLEED, 
clinicaltrials.gov, clinical studies.org.
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